探討三氧化二砷聯(lián)合沙利度胺聯(lián)合治療骨髓增生異常綜合征的療效

朱翠霞

[摘要] 目的 對(duì)在骨髓增生異常綜合征的治療中應(yīng)用三氧化二砷和沙利度胺聯(lián)合治療的效果進(jìn)行分析和研究。方法 便利選擇該院收治的骨髓增生異常綜合征患者共計(jì)70例作為該次研究的納入對(duì)象，選取時(shí)間段為2017年1月—2019年6月，按照隨機(jī)數(shù)字表法將這些患者劃分為聯(lián)合用藥組和單一用藥組，每組35例。采用沙利度胺對(duì)單一用藥組患者進(jìn)行治療，在此基礎(chǔ)上，聯(lián)合應(yīng)用三氧化二砷治療聯(lián)合用藥組患者，對(duì)兩組患者的治療效果進(jìn)行分析和比較。結(jié)果 單一用藥組中有8例完全緩解、10例部分緩解、9例穩(wěn)定、8例無(wú)效，共計(jì)達(dá)到了51.4%的總有效率，聯(lián)合用藥組中有15例完全緩解、9例部分緩解、7例穩(wěn)定、4例無(wú)效，共計(jì)達(dá)到了68.6%的總有效率，聯(lián)合用藥組的總有效率明顯高于單一用藥組，組間差異有統(tǒng)計(jì)學(xué)意義（χ2=8.735，P<0.05）。單一用藥組中共計(jì)有1例腹瀉、2例便秘、1例肝功能損害，共計(jì)達(dá)到了11.4%的不良反應(yīng)發(fā)生率，聯(lián)合用藥組中共計(jì)有1例腹瀉、1例便秘、2例肝功能損害、1例上呼吸道感染，共計(jì)達(dá)到了14.3%的不良反應(yīng)發(fā)生率，聯(lián)合用藥組的不良反應(yīng)發(fā)生率與單一用藥組相比略高，差異無(wú)統(tǒng)計(jì)學(xué)意義（χ2=0.395，P>0.05）。結(jié)論 在骨髓增生異常綜合征的臨床治療中采用氧化二砷和沙利度胺聯(lián)合治療具有很好的效果，而且安全性更好。

[關(guān)鍵詞] 骨髓增生異常綜合征;三氧化二砷;沙利度胺;聯(lián)合用藥

[Abstract] Objective To analyze and study the effect of arsenic trioxide and thalidomide combined treatment in the treatment of myelodysplastic syndromes. Methods A total of 70 patients with myelodysplastic syndromes treated in the hospital were convenient selected as the subjects of this study. The period of time was from January 2017 to June 2019. These patients were divided into a combination drug group and single-dose group according to the random number table method， with 35 patients in each group. The thalidomide was used to treat patients in the single drug group. Based on this， arsenic trioxide was used in combination with the patients in the drug group to analyze and compare the treatment effects of the two groups of patients. Results Eight patients in the single-medicine group had complete remission， 10 patients had partial remission， 9 patients were stable， 8 patients were ineffective， and a total effective rate of 51.4% was achieved. 15 patients in the combination group had complete response， 9 patients had partial response， 7 cases were stable and 4 cases were ineffective， reaching a total effective rate of 68.6%. The total effective rate of the combined drug group was significantly higher than that of the single drug group， and the difference was statistically significant（χ2=8.735， P<0.05）. There were 1 case of diarrhea， 2 cases of constipation， and 1 case of liver function impairment in the monotherapy group， with a total incidence of adverse reactions of 11.4%. The combined group had 1 case of diarrhea， 1 case of constipation， and 2 cases of liver function impairment， 1 case of upper respiratory tract infection， a total of 14.3% of adverse reactions occurred. The incidence of adverse reactions in the combined drug group was slightly higher than that in the single drug group， but it was found to have no statistically significance after experience （χ2=0.395， P>0.05）. Conclusion The combined treatment of arsenic oxide and thalidomide in clinical treatment of myelodysplastic syndrome has good effect and better safety.